-
M.
Hofmann,
O.
Stoss,
T.
Gaiser,
H.
Kneitz,
P.
Heinmöller,
T.
Gutjahr,
M.
Kaufmann,
T.
Henkel,
J.
Rüschoff
(2007)
Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy
Journal of Clinical Pathology, 61
-
E.
Surmacz
(2003)
Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor
Oncogene, 22
-
Yaohui
Wang,
Yu
Liu,
Yueyao
Du,
W.
Yin,
Jinsong
Lu
(2013)
The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphoinositol-3 (PI3) kinase (PIK3CA) mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: a meta-analysis
Current Medical Research and Opinion, 29
-
Jessica
Christenson,
Erin
Denny,
S.
Kane
(2015)
t-Darpp overexpression in HER2-positive breast cancer confers a survival advantage in lapatinib
Oncotarget, 6
-
G.
Arpino,
L.
Wiechmann,
C.
Osborne,
R.
Schiff
(2008)
Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.
Endocrine reviews, 29 2
-
R.
Nahta,
L.
Yuan,
Bing
Zhang,
R.
Kobayashi,
F.
Esteva
(2005)
Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells.
Cancer research, 65 23
-
J.
Baselga,
I.
Bradbury,
H.
Eidtmann,
S.
Cosimo,
E.
Azambuja,
C.
Aura,
H.
Gómez,
P.
Dinh,
K.
Fauria,
V.
Dooren,
G.
Aktan,
A.
Goldhirsch,
Tsai-Wang
Chang,
Z.
Horváth,
M.
Coccia-Portugal,
J.
Dômont,
L.
Tseng,
G.
Kunz,
J.
Sohn,
V.
Semiglazov,
G.
Lerzo,
M.
Pálácova,
V.
Probachai,
L.
Pusztai,
M.
Untch,
R.
Gelber,
M.
Piccart-Gebhart
(2012)
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
The Lancet, 379
-
J.
Cortés,
P.
Fumoleau,
G.
Bianchi,
T.
Petrella,
K.
Gelmon,
X.
Pivot,
S.
Verma,
J.
Albanell,
P.
Conte,
A.
Lluch,
S.
Salvagni,
V.
Servent,
L.
Gianni,
M.
Scaltriti,
G.
Ross,
J.
Dixon,
T.
Szado,
J.
Baselga
(2012)
Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 14
-
S.
Loibl,
J.
Bruey,
G.
Minckwitz,
J.
Huober,
Michael
Press,
S.
Darb-Esfahani,
C.
Solbach,
C.
Denkert,
H.
Tesch,
F.
Holms,
T.
Fehm,
K.
Mehta,
M.
Untch
(2011)
Validation of p95 as a predictive marker for trastuzumab-based therapy in primary HER2-positive breast cancer: A translational investigation from the neoadjuvant GeparQuattro study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 15_suppl
-
H.
Hartog,
J.
Wesseling,
H.
Boezen,
W.
Graaf
(2007)
The insulin-like growth factor 1 receptor in cancer: old focus, new future.
European journal of cancer, 43 13
-
F.
Castiglioni,
E.
Tagliabue,
M.
Campiglio,
S.
Pupa,
A.
Balsari,
S.
Ménard
(2006)
Role of exon-16-deleted HER2 in breast carcinomas.
Endocrine-related cancer, 13 1
-
M.
DiGiovanna,
D.
Stern,
S.
Edgerton,
S.
Whalen,
D.
Moore,
A.
Thor
(2005)
Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 6
-
Freddie
Hamdy,
Jenny
Donovan,
Athene,
Chris
Metcalfe,
M.
Davis,
R.
Martin,
Bollina
J.,
Andrew
Doble,
Alan
Doherty,
Gillatt,
Gnanapragasam
David,
O.
Hughes,
Howard,
A.
Paul,
E.
Paez,
P.
Powell,
M.
Mason,
J.
Oxley,
J.
Lane,
M.
Davis,
E.
Turner,
G.
Young,
E.
Walsh,
R.
Bryant,
P.
Bollina,
D.
Gillatt,
V.
Gnanapragasam,
O.
Hughes,
R.
Kockelbergh,
H.
Kynaston,
E.
Paez,
P.
Powell,
D.
Rosario,
E.
Rowe,
M.
Mason,
T.
Peters,
J.
Oxley,
N.
Williams,
J.
Staffurth,
D.
Neal
(2023)
The n e w e n g l a n d j o u r n a l of m e d i c i n e
-
L.
Gianni,
T.
Pieńkowski,
Y.
Im,
L.
Roman,
L.
Tseng,
Mei-Ching
Liu,
A.
Lluch,
E.
Starosławska,
J.
Haba-Rodríguez,
S.
Im,
J.
Pedrini,
B.
Poirier,
P.
Morandi,
V.
Semiglazov,
V.
Srimuninnimit,
G.
Bianchi,
T.
Szado,
J.
Ratnayake,
G.
Ross,
P.
Valagussa
(2012)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
The Lancet. Oncology, 13 1
-
N.
Norton,
R.
Olson,
M.
Pegram,
Kathleen
Tenner,
K.
Ballman,
R.
Clynes,
K.
Knutson,
E.
Perez
(2014)
Association Studies of Fcγ Receptor Polymorphisms with Outcome in HER2+ Breast Cancer Patients Treated with Trastuzumab in NCCTG (Alliance) Trial N9831
Cancer Immunology Research, 2
-
M.
Scaltriti,
F.
Rojo,
A.
Ocaña,
J.
Anido,
M.
Guzman,
J.
Cortés,
S.
Cosimo,
X.
Matías-Guiu,
S.
Cajal,
J.
Arribas,
J.
Baselga
(2007)
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.
Journal of the National Cancer Institute, 99 8
-
V.
Guarneri,
M.
Dieci,
A.
Frassoldati,
A.
Maiorana,
G.
Ficarra,
S.
Bettelli,
E.
Tagliafico,
S.
Bicciato,
D.
Generali,
K.
Cagossi,
G.
Bisagni,
S.
Sarti,
A.
Musolino,
C.
Ellis,
R.
Crescenzo,
P.
Conte
(2015)
Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
The oncologist, 20 9
-
S.
Hurvitz,
F.
André,
Zefei
Jiang,
Z.
Shao,
M.
Mano,
S.
Neciosup,
L.
Tseng,
Qingyuan
Zhang,
K.
Shen,
Donggeng
Liu,
L.
Dreosti,
H.
Burris,
M.
Toi,
M.
Buyse,
David
Cabaribere,
M.
Lindsay,
S.
Rao,
L.
Pacaud,
T.
Taran,
D.
Slamon
(2015)
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
The Lancet. Oncology, 16 7
-
M.
Shi,
Dan
Liu,
H.
Duan,
L.
Qian,
Lina
Wang,
Lijia
Niu,
Huipeng
Zhang,
Zheng
Yong,
Z.
Gong,
Lun
Song,
Ming
Yu,
Meiru
Hu,
Qing
Xia,
B.
Shen,
N.
Guo
(2010)
The β2-adrenergic receptor and Her2 comprise a positive feedback loop in human breast cancer cells
Breast Cancer Research and Treatment, 125
-
A.
Chakraborty,
C.
Zerillo,
M.
DiGiovanna
(2015)
In vitro and in vivo studies of the combination of IGF1R inhibitor figitumumab (CP-751,871) with HER2 inhibitors trastuzumab and neratinib
Breast Cancer Research and Treatment, 152
-
A.
Schneeweiss,
S.
Chia,
T.
Hickish,
Vernon
Harvey,
A.
Eniu,
R.
Hegg,
C.
Tausch,
J.
Seo,
Y.
Tsai,
J.
Ratnayake,
V.
Mcnally,
G.
Ross,
J.
Cortés
(2013)
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).
Annals of oncology : official journal of the European Society for Medical Oncology, 24 9
-
B.
Dave,
I.
Migliaccio,
M.
Gutiérrez,
Meng-Fen
Wu,
G.
Chamness,
H.
Wong,
A.
Narasanna,
A.
Chakrabarty,
S.
Hilsenbeck,
Jian
Huang,
M.
Rimawi,
R.
Schiff,
C.
Arteaga,
C.
Osborne,
Jenny
Chang
(2011)
Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 2
-
C.
Hudis
(2007)
Trastuzumab--mechanism of action and use in clinical practice.
The New England journal of medicine, 357 1
-
C.
Denkert,
S.
Loibl,
A.
Noske,
M.
Roller,
B.
Müller,
M.
Komor,
J.
Budczies,
S.
Darb-Esfahani,
R.
Kronenwett,
C.
Hanusch,
C.
Törne,
W.
Weichert,
K.
Engels,
C.
Solbach,
I.
Schrader,
M.
Dietel,
G.
Minckwitz
(2010)
Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 1
-
K.
Liang,
F.
Esteva,
C.
Albarracin,
K.
Stemke‐Hale,
Yang
Lu,
G.
Bianchini,
Ching-Yi
Yang,
Yong
Li,
Xinqun
Li,
Chun-Te
Chen,
G.
Mills,
G.
Hortobagyi,
J.
Mendelsohn,
M.
Hung,
Z.
Fan
(2010)
Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation.
Cancer cell, 18 5
-
Quantitation of p95HER2 in paraffin sections by using a p95–specific antibody and correlation with outcome in a cohort of trastuzumab treated breast cancer patients.
-
G.
Zhuang,
Dana
Brantley-Sieders,
D.
Vaught,
Jian
Yu,
Lu
Xie,
S.
Wells,
D.
Jackson,
R.
Muraoka-Cook,
C.
Arteaga,
Junya
Chen
(2010)
Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy.
Cancer research, 70 1
-
Xinyi
Wu,
K.
Senechal,
M.
Neshat,
Y.
Whang,
C.
Sawyers
(1998)
The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway.
Proceedings of the National Academy of Sciences of the United States of America, 95 26
-
Y.
Yarden
(2001)
The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities.
European journal of cancer, 37 Suppl 4
-
S.
Moulder,
F.
Yakes,
S.
Muthuswamy,
R.
Bianco,
J.
Simpson,
C.
Arteaga
(2001)
Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Cancer research, 61 24
-
S.
Kahlert,
S.
Nuedling,
Martin
Eickels,
Hans-Jürgen
Vetter,
R.
Meyer,
C.
Grohé
(2000)
Estrogen Receptor α Rapidly Activates the IGF-1 Receptor Pathway*
The Journal of Biological Chemistry, 275
-
I.
Majewski,
P.
Nuciforo,
L.
Mittempergher,
A.
Bosma,
H.
Eidtmann,
E.
Holmes,
C.
Sotiriou,
D.
Fumagalli,
J.
Jiménez,
C.
Aura,
L.
Prudkin,
Maria
Díaz-Delgado,
L.
Peña,
S.
Loi,
C.
Ellis,
N.
Schultz,
E.
Azambuja,
N.
Harbeck,
M.
Piccart-Gebhart,
R.
Bernards,
J.
Baselga
(2015)
PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 12
-
Z.
Wainberg,
A.
Anghel,
A.
Rogers,
Amrita
Desai,
O.
Kalous,
D.
Conklin,
Raul
Ayala,
Neil
O’Brien,
C.
Quadt,
M.
Akimov,
D.
Slamon,
R.
Finn
(2013)
Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer
Molecular Cancer Therapeutics, 12
-
P.
Kaufman,
G.
Broadwater,
K.
Lezon-Geyda,
L.
Dressler,
D.
Berry,
P.
Friedman,
E.
Winer,
C.
Hudis,
M.
Ellis,
A.
Seidman,
L.
Harris
(2007)
CALGB 150002: Correlation of HER2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840, paclitaxel (P) with or without T in HER2+ and HER2- metastatic breast cancer (MBC)
Journal of Clinical Oncology, 25
-
T.
Simoncini,
A.
Hafezi-Moghadam,
D.
Brazil,
K.
Ley,
W.
Chin,
J.
Liao
(2000)
Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase
Nature, 407
-
A.
Musolino,
N.
Naldi,
B.
Bortesi,
D.
Pezzuolo,
M.
Capelletti,
G.
Missale,
D.
Laccabue,
A.
Zerbini,
R.
Camisa,
G.
Bisagni,
T.
Neri,
A.
Ardizzoni
(2008)
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 11
-
Adrian
Lee,
Xiaojiang
Cui,
S.
Oesterreich
(2001)
Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research, 7 12 Suppl
-
Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer.
-
C.
Vogel,
M.
Cobleigh,
D.
Tripathy,
J.
Gutheil,
L.
Harris,
L.
Fehrenbacher,
D.
Slamon,
M.
Murphy,
W.
Novotny,
M.
Burchmore,
S.
Shak,
S.
Stewart,
M.
Press
(2023)
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
Journal of Clinical Oncology, 41
-
W.
Yin,
Yiwei
Jiang,
Z.
Shen,
Z.
Shao,
Jinsong
Lu
(2011)
Trastuzumab in the Adjuvant Treatment of HER2-Positive Early Breast Cancer Patients: A Meta-Analysis of Published Randomized Controlled Trials
PLoS ONE, 6
-
B.
Duman,
B.
Sahin,
A.
Açıkalın,
M.
Ergin,
S.
Zorludemir
(2013)
PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 18 1
-
A.
Faber,
R.
Corcoran,
H.
Ebi,
L.
Sequist,
B.
Waltman,
Euiheon
Chung,
J.
Incio,
S.
Digumarthy,
Sarah
Pollack,
Youngchul
Song,
A.
Muzikansky,
E.
Lifshits,
S.
Roberge,
E.
Coffman,
C.
Benes,
H.
Gómez,
J.
Baselga,
C.
Arteaga,
M.
Rivera,
D.
Dias-Santagata,
R.
Jain,
J.
Engelman
(2011)
BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors.
Cancer discovery, 1 4
-
D.
Slamon,
G.
Clark,
S.
Wong,
W.
Levin,
A.
Ullrich,
W.
McGuire
(1987)
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
Science, 235 4785
-
J.
Baselga,
S.
Verma,
J.
Ro,
J.
Huober,
E.
Guardino,
L.
Fang,
S.
Olsen,
G.
Phillips,
S.
Haas,
M.
Pegram
(2013)
Abstract LB-63: Relationship between tumor biomarkers (BM) and efficacy in EMILIA, a phase III study of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC).
Cancer Research, 73
-
H.
Seol,
H.
Lee,
Yoomi
Choi,
H.
Lee,
Y.
Kim,
J.
Kim,
E.
Kang,
Sung-Won
Kim,
S.
Park
(2012)
Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance
Modern Pathology, 25
-
S.
Hamel,
A.
Bouchard,
C.
Ferrario,
S.
Hassan,
A.
Aguilar-Mahecha,
M.
Buchanan,
Louise
Quenneville,
W.
Miller,
M.
Basik
(2010)
Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers
Breast Cancer Research and Treatment, 120
-
Validation of p95 as a predictive marker for trastuzumab-based therapy in primary HER2–positive breast cancer.
-
Y.
Nieto,
F.
Nawaz,
Roy
Jones,
E.
Shpall,
S.
Nawaz
(2007)
Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 28
-
M.
Scaltriti,
S.
Chandarlapaty,
L.
Prudkin,
C.
Aura,
J.
Jiménez,
P.
Angelini,
Gertrudis
Sánchez,
M.
Guzman,
J.
Parra,
C.
Ellis,
R.
Gagnon,
M.
Koehler,
H.
Gómez,
C.
Geyer,
D.
Cameron,
J.
Arribas,
N.
Rosen,
J.
Baselga
(2010)
Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor
Clinical Cancer Research, 16
-
Erica,
Veera,
W.
Lily,
K.
Sloan,
S.
Priceman,
Benjamin
Cox,
Stephanie
Yu,
M.
Pimentel,
Tangkanangnukul,
J.
Arevalo,
K.
Morizono,
Breanne
Karanikolas,
A.
Sood,
S.
Cole
(2010)
Cancer esearch oenvironment and Immunology Sympathetic Nervous System Induces a Metastatic R tch in Primary Breast Cancer
-
D.
Cameron,
M.
Casey,
M.
Press,
D.
Lindquist,
T.
Pieńkowski,
C.
Romieu,
S.
Chan,
A.
Jagiełło-Gruszfeld,
B.
Kaufman,
J.
Crown,
A.
Chan,
M.
Campone,
P.
Viens,
N.
Davidson,
V.
Gorbounova,
J.
Raats,
D.
Skarlos,
B.
Newstat,
D.
Roychowdhury,
P.
Paoletti,
C.
Oliva,
S.
Rubin,
S.
Stein,
C.
Geyer
(2008)
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
Breast Cancer Research and Treatment, 112
-
W.
Xia,
R.
Mullin,
B.
Keith,
Lei-hua
Liu,
Hong
Ma,
D.
Rusnak,
G.
Owens,
K.
Alligood,
N.
Spector
(2002)
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
Oncogene, 21
-
B.
Kaufman,
J.
Mackey,
M.
Clemens,
P.
Bapsy,
A.
Vaid,
A.
Wardley,
S.
Tjulandin,
M.
Jahn,
M.
Lehle,
A.
Feyereislova,
C.
Révil,
A.
Jones
(2009)
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 33
-
J.
Carpten,
Andrew
Faber,
C.
Horn,
Gregory
Donoho,
S.
Briggs,
C.
Robbins,
G.
Hostetter,
S.
Boguslawski,
T.
Moses,
S.
Savage,
M.
Uhlik,
A.
Lin,
Jian
Du,
Y.
Qian,
D.
Zeckner,
G.
Tucker-Kellogg,
J.
Touchman,
K.
Patel,
S.
Mousses,
M.
Bittner,
R.
Schevitz,
M.
Lai,
K.
Blanchard,
James
Thomas
(2007)
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
Nature, 448
-
Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+BC).
-
M.
Scaltriti,
P.
Eichhorn,
J.
Cortés,
L.
Prudkin,
C.
Aura,
J.
Jiménez,
S.
Chandarlapaty,
V.
Serra,
A.
Prat,
Y.
Ibrahim,
M.
Guzman,
M.
Gili,
Olga
Rodríguez,
S.
Rodríguez,
J.
Pérez,
S.
Green,
S.
Mai,
N.
Rosen,
C.
Hudis,
J.
Baselga
(2011)
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients
Proceedings of the National Academy of Sciences, 108
-
The sympathetic nervous system induces a metastatic switch in primary breast cancer.
-
F.
André,
R.
O'Regan,
M.
Ozguroglu,
M.
Toi,
Bing-he
Xu,
G.
Jerusalem,
N.
Masuda,
S.
Wilks,
F.
Arena,
C.
Isaacs,
Y.
Yap,
Z.
Pápai,
I.
Láng,
A.
Armstrong,
G.
Lerzo,
M.
White,
K.
Shen,
J.
Litton,
David
Chen,
Yufen
Zhang,
S.
Ali,
T.
Taran,
L.
Gianni
(2014)
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.
The Lancet. Oncology, 15 6
-
D.
Shattuck,
Jamie
Miller,
K.
Carraway,
C.
Sweeney
(2008)
Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells.
Cancer research, 68 5
-
Alastair
Bartlett,
J.
Starcyznski,
T.
Robson,
A.
MacLellan,
Fiona
Campbell,
C.
Velde,
A.
Hasenburg,
C.
Markopoulos,
C.
Seynaeve,
D.
Rea,
J.
Bartlett
(2011)
Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition.
American journal of clinical pathology, 136 2
-
Kory
Alderson,
P.
Sondel
(2011)
Clinical Cancer Therapy by NK Cells via Antibody-Dependent Cell-Mediated Cytotoxicity
Journal of Biomedicine and Biotechnology, 2011
-
D.
Liu,
Z.
Yang,
T.
Wang,
H.
Chen,
Y.
Hu,
C.
Hu,
L.
Guo,
Q.
Deng,
Y.
Liu,
M.
Yu,
M.
Shi,
N.
Du,
N.
Guo
(2015)
β2-AR signaling controls trastuzumab resistance-dependent pathway
Oncogene, 35
-
F.
Sato,
S.
Saji,
M.
Toi
(2015)
Genomic tumor evolution of breast cancer
Breast Cancer, 23
-
Lori
Jerome,
L.
Shiry,
B.
Leyland-Jones
(2003)
Deregulation of the IGF axis in cancer: epidemiological evidence and potential therapeutic interventions.
Endocrine-related cancer, 10 4
-
(2013)
Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer
-
David
Schwartz
(1990)
A Hitchhiker’s Guide to the NIEHS Strategic Plan
Environmental Health Perspectives, 114
-
D.
Rusnak,
K.
Affleck,
S.
Cockerill,
C.
Stubberfield,
Robert
Harris,
M.
Page,
K.
Smith,
S.
Guntrip,
M.
Carter,
R.
Shaw,
A.
Jowett,
J.
Stables,
P.
Topley,
E.
Wood,
P.
Brignola,
S.
Kadwell,
B.
Reep,
R.
Mullin,
K.
Alligood,
B.
Keith,
R.
Crosby,
D.
Murray,
W.
Knight,
T.
Gilmer,
K.
Lackey
(2001)
The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.
Cancer research, 61 19
-
J.
Baselga,
J.
Albanell,
M.
Molina,
J.
Arribas
(2001)
Mechanism of action of trastuzumab and scientific update.
Seminars in oncology, 28 5 Suppl 16
-
C.
O'Sullivan,
R.
Connolly
(2014)
Pertuzumab and its accelerated approval: evolving treatment paradigms and new challenges in the management of HER2-positive breast cancer.
Oncology, 28 3
-
E.
Perez,
E.
Thompson,
K.
Ballman,
S.
Anderson,
Y.
Asmann,
Krishna
Kalari,
J.
Eckel-Passow,
A.
Dueck,
Kathleen
Tenner,
J.
Jen,
Jian-Bing
Fan,
X.
Geiger,
A.
McCullough,
Beiyun
Chen,
R.
Jenkins,
G.
Sledge,
E.
Winer,
J.
Gralow,
M.
Reinholz
(2015)
Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 7
-
P.
Brennan,
T.
Kumagai,
A.
Berezov,
R.
Murali,
M.
Greene
(2002)
HER2/Neu: mechanisms of dimerization/oligomerization
Oncogene, 21
-
J.
Arribas,
J.
Baselga,
Kim
Pedersen,
J.
Parra-Palau
(2011)
p95HER2 and breast cancer.
Cancer research, 71 5
-
(2011)
The beta2-adrenergic receptor and Her2 comprise a positive feedback loop in human breast cancer cells
-
D.
Mitra,
M.
Brumlik,
Stella
Okamgba,
Yun
Zhu,
T.
Duplessis,
Jenny
Parvani,
S.
Lesko,
E.
Brogi,
F.
Jones
(2009)
An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance
Molecular Cancer Therapeutics, 8
-
C.
Benz,
G.
Scott,
J.
Sarup,
Randolph
Johnson,
D.
Tripathy,
E.
Coronado,
H.
Shepard,
C.
Osborne
(1992)
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
Breast Cancer Research and Treatment, 24
-
(2001)
Crosstalk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer
-
W.
Hanna,
J.
Rüschoff,
M.
Bilous,
R.
Coudry,
M.
Dowsett,
R.
Osamura,
F.
Penault-Llorca,
M.
Vijver,
G.
Viale
(2014)
HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity
Modern Pathology, 27
-
C.
Gewinner,
Z.
Wang,
A.
Richardson,
J.
Teruya-Feldstein,
D.
Etemadmoghadam,
D.
Bowtell,
J.
Barretina,
William
Lin,
L.
Rameh,
L.
Salmena,
P.
Pandolfi,
L.
Cantley
(2009)
Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling.
Cancer cell, 16 2
-
Molecular pathways: HER3 targeted therapy.
-
S.
Park,
Koichi
Ito,
William
Olcott,
Igor
Katsyv,
Gwyneth
Halstead-Nussloch,
H.
Irie
(2015)
PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2+ breast cancer cells by inducing Bim
Breast Cancer Research : BCR, 17
-
L.
Neckers
(2007)
Heat shock protein 90: The cancer chaperone
Journal of Biosciences, 32
-
J.
Baselga,
J.
Cortés,
S.
Im,
E.
Clark,
G.
Ross,
A.
Kiermaier,
S.
Swain
(2014)
Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 33
-
Joshua
McMichael,
L.
Fulton,
D.
Dooling,
Li
Ding,
R.
Elaine,
Mardis,
R.
Wilson,
Miruna,
Balasundaram,
R.
Carlsen,
Candace
Carter,
Andy,
M
Chu,
E.
Chuah,
Noreen
Dhalla,
Ranabir,
Guin,
Carrie
Hirst,
M.
Hirst,
R.
Holt,
D.
Lee,
Michael,
Mayo,
Richard
Moore,
A.
Mungall,
E.
Pleasance,
A.
GordonRobertson,
J.
Schein,
A.
Shafiei,
Payal
Sipahimalani,
Jared
Slobodan,
Yongjun
Zhao,
I.
Birol,
Steven
Jones,
R.
Onofrio,
S.
Carter,
S.
Schumacher,
B.
Tabak,
Bryan
Hernandez,
R.
Beroukhim,
W.
Winckler,
S.
Gabriel,
A.
Prat,
Grace
Silva,
Jerry
Usary,
Douglas
Voet,
N.
Gehlenborg,
Mike
Lawrence,
Lihua,
Zou,
Pei
Lin,
R.
Jing,
JuokCho,
Raktim,
Sinha,
R.
Park,
Marc-Danie
Nazaire,
James
Robinson,
Helga,
Thorvaldsdottir,
J.
Mesirov,
Peter
Park,
L.
Chin,
R.
Kreisberg,
A.
Jacobsen,
Rileen
Sinha,
B.
Reva,
R.
Shen,
B.
Taylor,
Tod
Casasent,
A.
Unruh,
Joshua
Stuart,
Jingchun
Zhu,
Chris
Szeto,
G.
Scott,
C.
Yau,
Evan,
O.
Paull,
Daniel
Carlin,
Artem
Sokolov,
J.
Thusberg,
S.
Mooney,
Jay
Bowen,
N.
Ramirez,
D.
Aaron,
Black,
R.
Pyatt,
P.
White,
E.
Zmuda,
J.
Frick,
M.
Tara,
Lichtenberg,
Robin
Brookens,
Myra
George,
Mark
Gerken,
A.
Hollie,
Harper,
K.
Leraas,
Teresa
Tabler
(2013)
Comprehensive molecular portraits of human breast tumours
Yearbook of Pathology and Laboratory Medicine, 2013
-
First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2–positive early breast cancer (EBC).
-
J.
Baselga,
J.
Cortés,
Sung-Bae
Kim,
S.
Im,
R.
Hegg,
Y.
Im,
L.
Roman,
J.
Pedrini,
T.
Pieńkowski,
A.
Knott,
E.
Clark,
M.
Benyunes,
G.
Ross,
S.
Swain
(2012)
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
The New England journal of medicine, 366 2
-
Bolin
Liu,
Zeying
Fan,
S.
Edgerton,
Xiaohe
Yang,
S.
Lind,
A.
Thor
(2011)
Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions
Cell Cycle, 10
-
(2012)
CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
-
H.
Cheng,
K.
Ballman,
M.
Vassilakopoulou,
A.
Dueck,
M.
Reinholz,
K.
Tenner,
J.
Gralow,
C.
Hudis,
N.
Davidson,
G.
Fountzilas,
A.
McCullough,
B.
Chen,
A.
Psyrri,
D.
Rimm,
E.
Perez
(2014)
EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial
British Journal of Cancer, 111
-
S.
Lutgendorf,
A.
Sood,
M.
Antoni
(2010)
Host factors and cancer progression: biobehavioral signaling pathways and interventions.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 26
-
Clinical Medicine Insights: Oncology
-
A.
Motoyama,
N.
Hynes,
H.
Lane
(2002)
The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Cancer research, 62 11
-
perinde,
Xueguang
Jin,
J.
Banerjee,
E.
Penuel,
Anasuya
Saha,
G.
Diedrich,
N.
Huang,
K.
Leitzel,
J.
Weidler,
Suhail
Ali,
E.
Fuchs,
C.
Singer,
Angelika
Köstler,
M.
Bates,
G.
Parry,
J.
Winslow,
A.
Lipton
(2010)
Clinical Cancer esearch ing , Diagnosis , Prognosis ntitation of p 95 HER 2 in Paraffin Sections by Using a-Specific Antibody and Correlation with Outcome in R ohort of Trastuzumab-Treated Breast Cancer Patients
-
S.
Johnston,
J.
Pippen,
X.
Pivot,
M.
Lichinitser,
S.
Sadeghi,
V.
Diéras,
H.
Gómez,
G.
Romieu,
A.
Manikhas,
M.
Kennedy,
M.
Press,
J.
Maltzman,
A.
Florance,
L.
O’Rourke,
C.
Oliva,
S.
Stein,
M.
Pegram
(2009)
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 33
-
Antonio
Wolff,
M.
Hammond,
Jared
Schwartz,
K.
Hagerty,
D.
Allred,
Richard
Cote,
M.
Dowsett,
P.
Fitzgibbons,
Wedad
Hanna,
A.
Langer,
L.
McShane,
S.
Paik,
M.
Pegram,
Edith
Perez,
Michael
Press,
A.
Rhodes,
C.
Sturgeon,
S.
Taube,
R.
Tubbs,
Gail
Vance,
Marc
Vijver,
Thomas
Wheeler,
Daniel
Hayes
(2006)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
Archives of pathology & laboratory medicine, 131 1
-
E.
Mayer,
J.
Baurain,
J.
Sparano,
L.
Strauss,
M.
Campone,
P.
Fumoleau,
H.
Rugo,
A.
Awada,
O.
Sy,
A.
Llombart-Cussac
(2011)
A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor–Positive Breast Cancer
Clinical Cancer Research, 17
-
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
-
Antonio
Wolff,
M.
Hammond,
David
Hicks,
M.
Dowsett,
Lisa
McShane,
Kimberly
Allison,
D.
Allred,
John
Bartlett,
M.
Bilous,
P.
Fitzgibbons,
W.
Hanna,
Robert
Jenkins,
P.
Mangu,
S.
Paik,
Edith
Perez,
Michael
Press,
Patricia
Spears,
Gail
Vance,
G.
Viale,
Daniel
Hayes
(2014)
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
Archives of pathology & laboratory medicine, 138 2
-
(2013)
College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer
-
G.
Vance,
T.
Barry,
K.
Bloom,
P.
Fitzgibbons,
D.
Hicks,
R.
Jenkins,
D.
Persons,
R.
Tubbs,
M.
Hammond
(2009)
Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines.
Archives of pathology & laboratory medicine, 133 4
-
T.
Miller,
B.
Rexer,
J.
Garrett,
C.
Arteaga
(2011)
Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer
Breast Cancer Research : BCR, 13
-
(2013)
College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancerCollege of American Pathologists clinical practice guideline update
-
(2016)
β2-AR signaling controls trastuzumab resistancedependent pathway. Oncogene
-
I.
Dahabreh,
H.
Linardou,
F.
Siannis,
G.
Fountzilas,
S.
Murray
(2008)
Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials.
The oncologist, 13 6
-
(2013)
p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer
-
Ksenija
Asić
(2016)
Dominant mechanisms of primary resistance differ from dominant mechanisms of secondary resistance to targeted therapies.
Critical reviews in oncology/hematology, 97
-
L.
Gianni,
G.
Bianchini,
P.
Valagussa,
A.
Belousov,
Marlene
Thomas,
G.
Ross,
L.
Pusztai
(2012)
Abstract S6-7: Adaptive immune system and immune checkpoints are associated with response to pertuzumab (P) and trastuzumab (H) in the NeoSphere study
Cancer Research, 72
-
R.
Pinkas-Kramarski,
L.
Soussan,
H.
Waterman,
G.
Levkowitz,
I.
Alroy,
L.
Klapper,
S.
Lavi,
R.
Seger,
B.
Ratzkin,
M.
Sela,
Y.
Yarden
(1996)
Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions.
The EMBO Journal, 15
-
S.
Verma,
D.
Miles,
L.
Gianni,
I.
Krop,
M.
Welslau,
J.
Baselga,
M.
Pegram,
D.
Oh,
V.
Diéras,
E.
Guardino,
L.
Fang,
Michael
Lu,
S.
Olsen,
K.
Blackwell
(2012)
Trastuzumab emtansine for HER2-positive advanced breast cancer.
The New England journal of medicine, 367 19
-
K.
Blackwell,
H.
Burstein,
A.
Storniolo,
H.
Rugo,
G.
Sledge,
M.
Koehler,
C.
Ellis,
M.
Casey,
S.
Vukelja,
J.
Bischoff,
J.
Baselga,
J.
O’Shaughnessy
(2010)
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 7
-
J.
Campbell,
M.
Karolak,
Yun
Ma,
D.
Perrien,
S.
Masood-Campbell,
Niki
Penner,
S.
Munoz,
A.
Zijlstra,
Xiangli
Yang,
J.
Sterling,
Florent
Elefteriou
(2012)
Stimulation of Host Bone Marrow Stromal Cells by Sympathetic Nerves Promotes Breast Cancer Bone Metastasis in Mice
PLoS Biology, 10
-
S.
Hurvitz,
D.
Betting,
H.
Stern,
E.
Quinaux,
Jeremy
Stinson,
S.
Seshagiri,
Ying-Ling
Zhao,
M.
Buyse,
J.
Mackey,
A.
Driga,
Sambasivarao
Damaraju,
M.
Sliwkowski,
N.
Robert,
V.
Valero,
J.
Crown,
C.
Falkson,
A.
Brufsky,
T.
Pieńkowski,
W.
Eiermann,
Miguel
Martín,
V.
Bée,
O.
Marathe,
D.
Slamon,
J.
Timmerman
(2012)
Analysis of Fcγ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients
Clinical Cancer Research, 18
-
S.
Aaltomaa,
P.
Lipponen,
M.
Eskelinen,
V.
Kosma,
S.
Marin,
E.
Alhava,
K.
Syrjänen
(1992)
Lymphocyte infiltrates as a prognostic variable in female breast cancer.
European journal of cancer, 28A 4-5
-
S.
Houston,
TA
Plunkett,
D.
Barnes,
P.
Smith,
R.
Rubens,
D.
Miles
(1999)
Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
British Journal of Cancer, 79
-
E.
Azambuja,
A.
Holmes,
M.
Piccart-Gebhart,
E.
Holmes,
S.
Cosimo,
R.
Swaby,
M.
Untch,
C.
Jackisch,
I.
Láng,
I.
Smith,
F.
Boyle,
Bing-he
Xu,
C.
Barrios,
E.
Perez,
H.
Azim,
Sung-Bae
Kim,
S.
Kuemmel,
Chiun-Sheng
Huang,
P.
Vuylsteke,
R.
Hsieh,
V.
Gorbunova,
A.
Eniu,
L.
Dreosti,
Natalia
Tavartkiladze,
R.
Gelber,
H.
Eidtmann,
J.
Baselga
(2014)
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
The Lancet. Oncology, 15 10
-
J.
Baselga,
K.
Gelmon,
S.
Verma,
A.
Wardley,
P.
Conte,
D.
Miles,
G.
Bianchi,
J.
Cortés,
V.
Mcnally,
G.
Ross,
P.
Fumoleau,
L.
Gianni
(2010)
Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 7
-
J.
Huober,
P.
Fasching,
S.
Paepke,
E.
Kubista,
M.
Barsoum,
D.
Wallwiener,
N.
Harbeck
(2009)
Letrozole in Combination with Trastuzumab Is Superior to Letrozole Monotherapy as First Line Treatment in Patients with Hormone-Receptor-Positive, HER2- Positive Metastatic Breast Cancer (MBC) – Results of theeLEcTRATrial.
Cancer Research, 69
-
S.
Modi,
A.
Stopeck,
M.
Gordon,
D.
Mendelson,
D.
Solit,
R.
Bagatell,
Weining
Ma,
J.
Wheler,
N.
Rosen,
L.
Norton,
G.
Cropp,
Robert
Johnson,
A.
Hannah,
C.
Hudis
(2007)
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 34
-
(2015)
CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer
-
D.
Koboldt,
R.
Fulton,
M.
McLellan,
Heather
Schmidt,
Joelle
Kalicki-Veizer,
Joshua
McMichael,
L.
Fulton,
D.
Dooling,
L.
Ding,
E.
Mardis,
R.
Wilson,
Adrian
Ally,
M.
Balasundaram,
Y.
Butterfield,
R.
Carlsen,
Candace
Carter,
Andy
Chu,
E.
Chuah,
Hye-Jung
Chun,
R.
Coope,
Noreen
Dhalla,
R.
Guin,
Carrie
Hirst,
M.
Hirst,
R.
Holt,
Darlene
Lee,
H.
Li,
Michael
Mayo,
Richard
Moore,
A.
Mungall,
E.
Pleasance,
A.
Robertson,
J.
Schein,
A.
Shafiei,
Payal
Sipahimalani,
Jared
Slobodan,
D.
Stoll,
Angela
Tam,
N.
Thiessen,
R.
Varhol,
N.
Wye,
Thomas
Zeng,
Yongjun
Zhao,
I.
Birol,
Steven
Jones,
M.
Marra,
A.
Cherniack,
G.
Saksena,
R.
Onofrio,
Nam
Pho,
S.
Carter,
S.
Schumacher,
B.
Tabak,
Bryan
Hernandez,
Jeff
Gentry,
Huy
Nguyen,
A.
Crenshaw,
K.
Ardlie,
R.
Beroukhim,
W.
Winckler,
G.
Getz,
S.
Gabriel,
M.
Meyerson,
L.
Chin,
R.
Kucherlapati,
K.
Hoadley,
J.
Auman,
C.
Fan,
Yidi
Turman,
Yan
Shi,
Ling
Li,
M.
Topal,
Xiaping
He,
H.
Chao,
A.
Prat,
Grace
Silva,
M.
Iglesia,
Wei
Zhao,
Jerry
Usary,
J.
Berg,
Michael
Adams,
J.
Booker,
Junyuan
Wu,
Anisha
Gulabani,
T.
Bodenheimer,
A.
Hoyle,
J.
Simons,
Matthew
Soloway,
Lisle
Mose,
S.
Jefferys,
S.
Balu,
J.
Parker,
D.
Hayes,
C.
Perou,
Simeen
Malik,
S.
Mahurkar,
Hui
Shen,
D.
Weisenberger,
T.
Triche,
Phillip
Lai,
M.
Bootwalla,
D.
Maglinte,
B.
Berman,
D.
Berg,
S.
Baylin,
P.
Laird,
C.
Creighton,
L.
Donehower,
M.
Noble,
Douglas
Voet,
N.
Gehlenborg,
D.
Cara,
Juinhua
Zhang,
Hailei
Zhang,
Chang-Jiun
Wu,
Spring
Liu,
M.
Lawrence,
L.
Zou,
A.
Sivachenko,
Pei
Lin,
P.
Stojanov,
R.
Jing,
Juok
Cho,
Raktim
Sinha,
R.
Park,
Marc-Danie
Nazaire,
James
Robinson,
H.
Thorvaldsdóttir,
J.
Mesirov,
P.
Park,
Sheila
Reynolds,
R.
Kreisberg,
Brady
Bernard,
Ryan
Bressler,
Timo
Erkkilä,
Jake
Lin,
V.
Thorsson,
Wei
Zhang,
I.
Shmulevich,
G.
Ciriello,
Nils
Weinhold,
N.
Schultz,
Jianjiong
Gao,
E.
Cerami,
Benjamin
Gross,
A.
Jacobsen,
Rileen
Sinha,
B.
Aksoy,
Yevgeniy
Antipin,
B.
Reva,
R.
Shen,
B.
Taylor,
M.
Ladanyi,
C.
Sander,
Pavana
Anur,
P.
Spellman,
Yiling
Lu,
Wenbin
Liu,
R.
Verhaak,
G.
Mills,
R.
Akbani,
Nianxiang
Zhang,
B.
Broom,
Tod
Casasent,
Chris
Wakefield,
A.
Unruh,
K.
Baggerly,
K.
Coombes,
J.
Weinstein,
D.
Haussler,
C.
Benz,
Joshua
Stuart,
S.
Benz,
Jingchun
Zhu,
C.
Szeto,
G.
Scott,
C.
Yau,
Evan
Paull,
Daniel
Carlin,
Christopher
Wong,
Artem
Sokolov,
J.
Thusberg,
S.
Mooney,
S.
Ng,
Theodore
Goldstein,
K.
Ellrott,
Mia
Grifford,
C.
Wilks,
Singer
Ma,
Brian
Craft,
Chunhua
Yan,
Ying
Hu,
D.
Meerzaman,
J.
Gastier-Foster,
Jay
Bowen,
N.
Ramirez,
Aaron
Black,
R.
Pyatt,
P.
White,
E.
Zmuda,
J.
Frick,
T.
Lichtenberg,
Robin
Brookens,
Myra
George,
M.
Gerken,
H.
Harper,
K.
Leraas,
L.
Wise,
Teresa
Tabler,
Cynthia
McAllister,
T.
Barr,
Melissa
Hart-Kothari,
Katherine
Tarvin,
Charles
Saller,
G.
Sandusky,
Colleen
Mitchell,
M.
Iacocca,
Jennifer
Brown,
B.
Rabeno,
Christine
Czerwinski,
N.
Petrelli,
Oleg
Dolzhansky,
M.
Abramov,
Olga
Voronina,
O.
Potapova,
J.
Marks,
W.
Suchorska,
D.
Murawa,
W.
Kycler,
Matthew
Ibbs,
Konstanty
Korski,
A.
Spychała,
P.
Murawa,
Jacek
Brzeziński,
Hanna
Perz,
Radoslaw
Łaźniak,
M.
Teresiak,
Honorata
Tatka,
E.
Leporowska,
M.
Bogusz-Czerniewicz,
J.
Malicki,
A.
Mackiewicz,
M.
Wiznerowicz,
X.
Le,
B.
Kohl,
N.
Tien,
Richard
Thorp,
N.
Bang,
H.
Sussman,
Bui
Phu,
R.
Hajek,
N.
Hung,
H.
Thang,
K.
Khan,
R.
Penny,
D.
Mallery,
Erin
Curley,
C.
Shelton,
P.
Yena,
J.
Ingle,
F.
Couch,
W.
Lingle,
T.
King,
A.
González-Angulo,
Mary
Dyer,
Shuying
Liu,
Xiaolong
Meng,
Modesto
Patangan,
F.
Waldman,
H.
Stoppler,
W.
Rathmell,
L.
Thorne,
Meijuan
Huang,
L.
Boice,
Ashley
Hill,
C.
Morrison,
Carmelo
Gaudioso,
W.
Bshara,
K.
Daily,
Sophie
Egea,
M.
Pegram,
C.
Gomez-Fernandez,
R.
Dhir,
R.
Bhargava,
A.
Brufsky,
C.
Shriver,
J.
Hooke,
J.
Campbell,
R.
Mural,
Hai
Hu,
S.
Somiari,
C.
Larson,
B.
Deyarmin,
L.
Kvecher,
A.
Kovatich,
M.
Ellis,
T.
Stricker,
K.
White,
O.
Olopade,
C.
Luo,
Y.
Chen,
R.
Bose,
Li-Wei
Chang,
Andrew
Beck,
T.
Pihl,
M.
Jensen,
R.
Sfeir,
A.
Kahn,
A.
Chu,
Prachi
Kothiyal,
Zhining
Wang,
E.
Snyder,
J.
Pontius,
Brenda
Ayala,
M.
Backus,
Jessica
Walton,
J.
Baboud,
D.
Berton,
M.
Nicholls,
Deepak
Srinivasan,
R.
Raman,
Stanley
Girshik,
Peter
Kigonya,
S.
Alonso,
Rashmi
Sanbhadti,
S.
Barletta,
D.
Pot,
Margi
Sheth,
John
Demchok,
K.
Shaw,
Liming
Yang,
G.
Eley,
M.
Ferguson,
R.
Tarnuzzer,
J.
Zhang,
Laura
Dillon,
K.
Buetow,
P.
Fielding,
B.
Ozenberger,
M.
Guyer,
H.
Sofia,
Jacqueline
Palchik
(2012)
Comprehensive molecular portraits of human breast tumors
Nature, 490
-
S.
Loi,
S.
Michiels,
R.
Salgado,
N.
Sirtaine,
V.
Jose,
D.
Fumagalli,
David
Brown,
P.
Kellokumpu-Lehtinen,
P.
Bono,
V.
Kataja,
C.
Desmedt,
M.
Piccart-Gebhart,
S.
Loibl,
M.
Untch,
C.
Denkert,
M.
Smyth,
H.
Joensuu,
C.
Sotiriou
(2013)
Abstract S1-05: Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC)
Cancer Research, 73
-
E.
Perez,
F.
Baehner,
S.
Butler,
E.
Thompson,
A.
Dueck,
F.
Jamshidian,
D.
Cherbavaz,
C.
Yoshizawa,
S.
Shak,
P.
Kaufman,
N.
Davidson,
J.
Gralow,
Y.
Asmann,
K.
Ballman
(2015)
The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831
Breast Cancer Research : BCR, 17
-
S.
Swain,
J.
Baselga,
Sung-Bae
Kim,
J.
Ro,
V.
Semiglazov,
M.
Campone,
E.
Ciruelos,
J.
Ferrero,
A.
Schneeweiss,
S.
Heeson,
E.
Clark,
G.
Ross,
M.
Benyunes,
J.
Cortés
(2015)
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
The New England journal of medicine, 372 8
-
J.
Garrett,
M.
Olivares,
C.
Rinehart,
N.
Granja-Ingram,
V.
Sanchez,
A.
Chakrabarty,
B.
Dave,
R.
Cook,
W.
Pao,
Eliot
McKinely,
H.
Manning,
Jenny
Chang,
C.
Arteaga
(2011)
Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase
Proceedings of the National Academy of Sciences, 108
-
S.
Chandarlapaty,
M.
Scaltriti,
P.
Angelini,
Q.
Ye,
M.
Guzman,
C.
Hudis,
L.
Norton,
D.
Solit,
J.
Arribas,
J.
Baselga,
N.
Rosen
(2009)
Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth
Oncogene, 29
-
(2015)
Genomic tumor evolution of
-
A.
Gallardo,
E.
Lerma,
D.
Escuin,
A.
Tibau,
J.
Muñoz,
B.
Ojeda,
A.
Barnadas,
E.
Adrover,
L.
Sanchez-Tejada,
D.
Giner,
F.
Ortiz-Martínez,
G.
Peiró
(2012)
Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas
British Journal of Cancer, 106
-
N.
Hellyer,
M.
Kim,
J.
Koland
(2001)
Heregulin-dependent Activation of Phosphoinositide 3-Kinase and Akt via the ErbB2/ErbB3 Co-receptor*
The Journal of Biological Chemistry, 276
-
J.
Baselga,
Gail
Phillips,
S.
Verma,
J.
Ro,
J.
Huober,
A.
Guardino,
M.
Samant,
S.
Olsen,
S.
Haas,
M.
Pegram
(2016)
Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
Clinical Cancer Research, 22
-
(2012)
NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
-
Yen-chao
Wang,
G.
Morrison,
R.
Gillihan,
Jun
Guo,
R.
Ward,
Xiaoyong
Fu,
Maria
Botero,
N.
Healy,
N.
Healy,
S.
Hilsenbeck,
G.
Phillips,
G.
Chamness,
M.
Rimawi,
C.
Osborne,
R.
Schiff
(2011)
Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers -- role of estrogen receptor and HER2 reactivation
Breast Cancer Research : BCR, 13
-
K.
Gala,
S.
Chandarlapaty
(2014)
Molecular Pathways Molecular Pathways : HER 3 Targeted Therapy
-
R.
Ferris,
E.
Jaffee,
S.
Ferrone
(2010)
Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 28
-
M.
Martínez,
J.
Pérez-Fidalgo,
P.
Martín-Martorell,
J.
Cejalvo,
V.
Pons,
B.
Bermejo,
Miguel
Martín,
J.
Albanell,
A.
Lluch
(2016)
Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature.
Critical reviews in oncology/hematology, 97
-
M.
Scaltriti,
V.
Serra,
E.
Normant,
M.
Guzman,
Olga
Rodríguez,
A.
Lim,
K.
Slocum,
K.
West,
Varenka
Rodriguez,
L.
Prudkin,
J.
Jiménez,
C.
Aura,
J.
Baselga
(2011)
Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
Molecular Cancer Therapeutics, 10
-
A.
Prat,
J.
Baselga
(2008)
The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2
Nature Clinical Practice Oncology, 5